Chanticleer — Merger or Acquisition (January 2020)
21 slides from Chanticleer's merger presentation, Jan 13, 2020

Slide 1: Corporate Presentation January 2020
SSONNET BioTherapeutics This presentation confains forward looking statements that do not guarantee future performance Corporate Presentation January 2020

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about Sonnet BioTherapeutics based on management's current expectations which are subject fo known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “se

Slide 3: Corporate Background
Corporate Background Incorporated in New Jersey » Headquarters: Princeton, New Jersey » Other Locations: New York City, Geneva + Employees, Consultants and Contracted Scientists/Experts: Approximately 30 people + Internal Pipeline Focus: Oncology » Proprietary technology platform » Existing licensin

Slide 4: Corporate Highlights
Corporate Highlights Sonnet is a clinical stage biopharmaceutical company with a proprietary, modular biologic drug development platform We have a deep knowledge of cytokine biology, complemented by extensive drug discovery and development expertise Our corporate strategy comprises an internal thera

Slide 5: The Sonnet Platform
§ The Sonnet Platform Asset generation capabilities across major biologic drug classes Five Filed Patent Applications FAB construct design for numerous targets: Immunotherapy - Combination with checkpoint inhibitors Drug conjugation Vaccine Bone/Tissue Metastasis CAR-T SONNET BioTherapeufics Immunog

Slide 6: The Sonnet Technology Advantage
The Sonnet Technology Advantage Sonnet’s Fully Human Albumin Binding (F,AB) technology utilizes a single chain antibody fragment (scFv) capable of delivering one or two active drug compounds * Therapeutic payloads attached via A flexible linker peptides Therapeutic Following administration, Sonnet's

Slide 7: Pipeline Overview
Pipeline Overview First wave pipeline will target IL-6, IL-12, IL-15, IL-18, GMcSF and TGFs FyAB Platform Progr Indications Chemotherapy Induced SON-080 (low dose IL-6) anphercl Neuropathy SON-1010 (IL12-F,,AB) Undisclosed Solid Tumor SON-1210 (IL15-F,,AB-IL12) Undisclosed Solid Tumor SON-2014 (GMcS

Slide 8: IL-6: A Disease Modifier of CIPN
IL-6: A Disease Modifier of CIPN CIPN Patient Populationt + >50% of cancer patients receiving chemotherapy develop CIPN + CIPN peak prevalence as high as 70% + New cases under chemotherapy in the US ~ 10 million Key Data Summary: + US cancer survivor population ~ 17 million + CIPN represents a signi

Slide 9: Neuroprotection by IL-6
Walério et al., 2002; 2Pizzi et al., 2004; Hakkoum et al., 2007; *Neurofit, 2003; SBensadoun et al., 2001 Neuroprotection by IL-6 In vitro, ex vivo and in vivo data validate the neuroprotective activity 1) IL-6 stimulates maturation of myelin- 2) IL-6 increases nerves regeneration 3) IL-6 protects n

Slide 10: IL-6 Intrinsically
IL-6 Intrinsically IL-6 maintains / restores nerve fiber density Rats (n = 10/group) 2 Taxol (6mg/kg/week, i.p.) 3 aD 3 a Do 14 028 pa 8 ttpptetetettettttesett = Bo IL-6 SC daily injection . 5 E 2 *p<0.05 Rats (n = 10/group) 2 Vincristine (0.15me/ke, ip.) 5 a z= ‘7 [Gaal Do pia pee © ttetetoeseteret

Slide 11: IL-6 is safe and well tolerated at the target dose
IL-6 is safe and well tolerated at the target dose Phase I/II clinical data * Condition: Thrombocytopenia * Side effect profile: Similar AEs and SAEs to controls, eg fever * Patients: n=213; all types also including Grade III/IV and rigor, headache, vomiting (at target dose range). cancer! * No exac

Slide 12: IL-6: Plan for Proof-of-Efficacy in CIPN Patients
IL-6: Plan for Proof-of-Efficacy in CIPN Patients Low dose, recombinant human IL-6 is safe in cancer patients Design of a randomized, double-blind, placebo-controlled trial is currently underway: Cancer survivors with at least 6-12 months of CIPN post-antineoplastic treatment 2-3 doses, subcutaneous

Slide 13: FcAB Constructs IL-12 and IL-15: Pharmacokinetic Half Life
§ FyAB Constructs IL-12 and IL-153: Pharmacokinetic Half Life The aim of this study was to demonstrate in mice, the pharmacokinetic (pK) behavior of naked IL-12 and IL-15 compared to the same interleukins linked to Sonnet’s F,AB domain Method: 8 mice C57B/ TP, Age 9.5 weeks dose IV, sacrificed @ 5,

Slide 14: anti-TGFb and anti-TGFb-FcAB: Evaluating Tumor Accumulation
anti-TGFgp and anti-TGFg-F,AB: Evaluating Tumor Accumulation An in vivo Demonstration of F,AB Proof-of-Concept Results show an accumulation and retention of F,,AB in the tumor Western blot analysis of Mouse 411 (TGFB-positive) tumor (~150mm+) extracts from mice terminated at 0.5, 4, 12 and 24-hours

Slide 15: IL12-FcAB vs IL-12: Tumor Reduction Data
§ IL12-F,AB vs IL-12: Tumor Reduction Data Evaluation of Single Dose (SD) IL12-F,AB (1.3ug) vs IL-12 (30ug) in B16F10 Melanoma (established @100 mm3 , n=8) Tumor Volume (mms) s 3 "™@ Placebo + 1L12-F,AB] (1.3ug. |SD) = Molar|0.9yg] of IL-12 A« 1L-12 (30ug, SD) 1:30 ratio of IL-12 SONNET BioTherapeut

Slide 16: IL12-FcAB vs IL-12: Dose Level Comparisons
IL12-F,,AB vs IL-12: Dose Level Comparisons Tumor Volume Changes Between Groups on Day 10 Post Treatment (Day 0 @ 100 mms) — IL12 vs 1L12-F,AB ; Single Dose 4 MM GI: Vehicle A MM G2: 11-12 § 3 2 * mc: on | ne $ S is £ » MM G4: IL 12 1oyg 2 MM G5: IL12-F,AB xo] = » MM G6: IL-2 20ua MM G7: 1L12-F,AB T

Slide 17: IL12-FcAB vs IL-12: Survival Data
IL12-F,,AB vs IL-12: Survival Data Single Dose 100 Median Days for 50% Tumor ‘ MM Gi: Vehicle ieschizoooemnts, £ a 10 Ss Ss 80+ MH c2: 1-12 4, @ 12 & “MD G3: 112 FyAB ne 14 S | feces = os 12 3 G4: IL-12 S 14 rt) 60-4 * 10ug = MM Gs: ee eS vy = = a a5 G6: IL-12 | a cl 5 20ug i 3 ae = G7. ILI2-FYAB +}

Slide 18: IL15-FcAB-IL12 vs IL12-FcAB
IL15-F,AB-IL12 vs IL12-F,AB Sonnet Bi-Specific Construct IL15-F,AB-IL12 Single I.V. Dose @ 100 mm? SC B16F10 1500 Synergistic Biologic Activity: _ Day 10 Tumor Volume (n=8) i IL-12: f IL-15 alpha receptor, ft IFN, E 1000 1 NK/T cells, } TH] and | Treg ia 3 IL-15: f IL-12 beta 1 receptor, t NK 3 500

Slide 19: IL15-FcAB-IL12 vs Concomitant IL-12 and IL-15
IL15-F,AB-IL12 vs Concomitant IL-12 and IL-15 Day 11 vehicle at +3000m$ not shown HMM IL-12 (5ug) + IL-15 (1g) MB IL12-F,,AB-IL15 (1.5yg) MB IL12-F,,AB-IL15 (6g) fl IL15-F,,AB-IL12 (1.5yg) MM IL15-F,,AB-IL12 (61g) Tumor Volume (mm’) B-IL12 shows better reduc’ IL12-F,,AB-IL15 or free, concomitantly d

Slide 20: Execution Efficiency
Execution Efficiency Integrating a Best-in-Class Platform with a World-Class Development Strategy Cell Line - 1L12-FyAB Soi Crus 1L15-F,AB-IL12 CRO Exploring innovative Cisiedl Leadership: Analytics - ae linical i clinical plans Studies SONNET Bio-outsource + Latham BioPharm 1L12-FyAB IL-6 IL15-FAB-

Slide 21: Leadership
Leadership Accomplished management team with deep experience in biotechnology ©@®@ 38s ® ® John Cini, PhD Chief Scientific Officer /Co-Founder PhD Jay Chief Financial Officer & Chief Business Officer ankaj Mohan Founder, CEO & Chairman Biotechnology entrepreneur with start- up, academic, large bioph
Source: SEC EDGAR · 425 filed Jan 13, 2020
More decks from Chanticleer Holdings Inc
Sonnet BioTherapeutics Holdings — Investor Presentation (September 2024)34 slides · Sep 9, 2024
Sonnet BioTherapeutics Holdings — Investor Presentation (June 2024)33 slides · Jun 14, 2024
Sonnet BioTherapeutics Holdings — Investor Presentation (May 2024)31 slides · May 14, 2024
Sonnet BioTherapeutics Holdings — Technical Presentation (April 2023)15 slides · Apr 18, 2023
Sonnet BioTherapeutics Holdings — Corporate Update (November 2022)12 slides · Nov 2, 2022
Cowen Healthcare Conference 202022 slides · Mar 3, 2020